Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma

被引：0
|
作者：
Go, Heounjeong
Kang, Mun Jung
Kim, Pil-Jong
Park, Ja-Min
Lee, Jae-Lyun
Park, Ji Young
Cho, Yong Mee
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-429
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
429
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Lee, Jae-Lyun
    Park, Ji Y.
    Park, Ja-Min
    Ro, Jae Y.
    Cho, Yong Mee
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (01) : 51 - 58
  • [2] Everolimus for Korean patients with metastatic renal cell carcinoma who have failed initial treatment of a vascular endothelial growth factor (VEGF): Tyrosine kinase inhibitor (TKI).
    Park, Kwonoh
    Ahn, Jin-Hee
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    Lee, Jae-Lyun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC)
    Pal, Sumanta K.
    Li, Min
    Wu, Xiwei
    Frankel, Paul
    [J]. BJU INTERNATIONAL, 2014, 114 : 13 - 13
  • [4] PHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC)
    Hutson, T.
    Rathmell, W. K.
    Feng, B.
    Robinson, M. O.
    Gyuris, J.
    Lin, J.
    Choueiri, T.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [5] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Park, Kwonoh
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. MEDICAL ONCOLOGY, 2012, 29 (05) : 3291 - 3297
  • [6] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Kwonoh Park
    Jae-Lyun Lee
    Inkeun Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    [J]. Medical Oncology, 2012, 29 : 3291 - 3297
  • [7] Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell Carcinoma
    Rudolph, Shannon
    Li, Mingjia
    Gheeya, Jinesh
    Zimmerman, Danielle
    Yin, Ming
    Clinton, Steven K.
    Parwani, Anil V.
    Yang, Yuanquan
    [J]. JCO PRECISION ONCOLOGY, 2023, 7
  • [8] Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
    Inkeun Park
    Jae-Lyun Lee
    Jin-Hee Ahn
    Dae-Ho Lee
    Kyoo-Hyung Lee
    Dalsan You
    In Gab Jeong
    Cheryn Song
    Bumsik Hong
    Jun Hyuk Hong
    Hanjong Ahn
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 1025 - 1035
  • [9] Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
    Park, Inkeun
    Lee, Jae-Lyun
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Lee, Kyoo-Hyung
    You, Dalsan
    Jeong, In Gab
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (05) : 1025 - 1035
  • [10] Identifying the genomic correlates of clinical benefit (CB) from immunotherapies (IO) and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKI) in metastatic renal cell carcinoma (mRCC)
    Dizman, Nazli
    Byron, Sara
    Lyou, Yung
    Bergerot, Paulo Gustavo
    Hsu, JoAnn
    Sam, Andre-Philippe
    Trieu, Denise Phan
    Trent, Jeffrey
    Pal, Sumanta Kumar
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345